List of the Best Biotech Stocks in India (2026)
India’s biotech industry is projected to reach $300 bn in valuation by 2030. Explore the best biotech stocks listed in NSE, sorted by market capitalisation.
List of Biotech Stocks in India (2026)
Biotechnology Stock Screener
Biotechnology Stock Screener: Analyse & Filter Indian Stocks on Tickertape
Created by
@tickertapetickertapeShowing 1 - 19 of 19 results
last updated at 6:30 AM IST
| NameStocks (19)↓ | ↓Sub-SectorSub-Sector↓ | ↓Market CapMarket Cap↓ | ↓Close PriceClose Price↓ | ↓PE RatioPE Ratio↓ | ↓1D Return1D Return↓ | ↓1M Return1M Return↓ | ↓6M Return6M Return↓ | ↓1Y Return1Y Return↓ | ↓PB RatioPB Ratio↓ | ↓Return on EquityReturn on Equity↓ | ↓ROCEROCE↓ | ↓Dividend YieldDiv Yield↓ | ↓Debt to EquityDebt to Equity↓ | ↓Volatility vs NiftyVolatility vs Nifty↓ | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Biocon LtdBIOCON | BiotechnologyBiotechnology | 69,339.1669,339.16 | 427.00427.00 | 179.82179.82 | 0.310.31 | 1.851.85 | 14.6914.69 | 11.6611.66 | 1.891.89 | 1.201.20 | 2.912.91 | 0.120.12 | 0.420.42 | 1.821.82 | |
| 2. | Anthem Biosciences LtdANTHEM | BiotechnologyBiotechnology | 45,573.7545,573.75 | 829.85829.85 | 77.0177.01 | 2.552.55 | 6.836.83 | 36.6236.62 | 10.3110.31 | 14.9814.98 | 21.7121.71 | 26.7826.78 | 0.250.25 | 0.020.02 | 2.162.16 | |
| 3. | Sai Life Sciences LtdSAILIFE | BiotechnologyBiotechnology | 28,307.4028,307.40 | 1,333.401,333.40 | 80.0280.02 | 1.391.39 | 7.677.67 | 51.6751.67 | 65.5565.55 | 13.1213.12 | 10.9610.96 | 20.9420.94 | -- | 0.170.17 | 2.402.40 | |
| 4. | Acutaas Chemicals LtdACUTAAS | BiotechnologyBiotechnology | 25,420.1625,420.16 | 3,116.403,116.40 | 71.3571.35 | 0.370.37 | -16.18-16.18 | 58.2258.22 | 135.34135.34 | 19.2619.26 | 15.8515.85 | 36.0836.08 | 0.160.16 | 0.010.01 | 3.063.06 | |
| 5. | Onesource Specialty Pharma LtdONESOURCE | BiotechnologyBiotechnology | 17,894.7017,894.70 | 1,560.501,560.50 | -251.64-251.64 | -3.65-3.65 | -7.66-7.66 | 32.5232.52 | -18.63-18.63 | 3.163.16 | -0.57-0.57 | 0.470.47 | -- | 0.130.13 | 2.912.91 | |
| 6. | Panacea Biotec LtdPANACEABIO | BiotechnologyBiotechnology | 2,593.662,593.66 | 423.45423.45 | -480.71-480.71 | 0.470.47 | -23.09-23.09 | 14.3114.31 | 2.802.80 | 3.083.08 | -1.00-1.00 | -0.14-0.14 | -- | 0.020.02 | 3.993.99 | |
| 7. | Hester Biosciences LtdHESTERBIO | BiotechnologyBiotechnology | 2,107.752,107.75 | 2,442.402,442.40 | 37.8837.88 | -1.42-1.42 | 12.1512.15 | 62.4362.43 | 15.3115.31 | 5.735.73 | 16.0216.02 | 16.5116.51 | 0.440.44 | 0.530.53 | 2.932.93 | |
| 8. | Q-Line Biotech LtdQLINE | BiotechnologyBiotechnology | 1,287.951,287.95 | 552.10552.10 | 22.6622.66 | 2.002.00 | -3.61-3.61 | 16.3316.33 | 16.3316.33 | 6.656.65 | 15.9915.99 | 33.2833.28 | -- | 0.880.88 | 3.043.04 | |
| 9. | 3B Blackbio DX Ltd3BBLACKBIO | BiotechnologyBiotechnology | 1,072.831,072.83 | 1,248.101,248.10 | 18.3118.31 | 0.080.08 | 2.192.19 | -20.23-20.23 | -19.46-19.46 | 3.963.96 | 19.2119.21 | 27.8627.86 | 0.400.40 | 0.000.00 | 3.303.30 | |
| 10. | Zenotech Laboratories LtdZENOTECH | BiotechnologyBiotechnology | 271.83271.83 | 44.8844.88 | -254.05-254.05 | 0.760.76 | -0.88-0.88 | 0.160.16 | -23.52-23.52 | 2.832.83 | 6.016.01 | 4.264.26 | -- | 0.000.00 | 2.892.89 | |
| 11. | AVIO Smart Market Stack LtdASMS | BiotechnologyBiotechnology | 213.81213.81 | 7.087.08 | 36.1236.12 | 0.850.85 | -3.01-3.01 | -34.93-34.93 | -45.45-45.45 | 7.577.57 | 6.396.39 | 19.0019.00 | -- | 0.010.01 | 3.983.98 | |
| 12. | CCME Global LtdCCME | BiotechnologyBiotechnology | 142.87142.87 | 104.45104.45 | -201.23-201.23 | -4.96-4.96 | -12.01-12.01 | 10.9810.98 | 233.60233.60 | 16.7516.75 | 51.7751.77 | -8.31-8.31 | -- | 0.000.00 | 4.294.29 | |
| 13. | Vivo Bio Tech LtdVIVOBIOT | BiotechnologyBiotechnology | 47.5347.53 | 21.2521.25 | -27.80-27.80 | -0.79-0.79 | -11.93-11.93 | -27.47-27.47 | -37.26-37.26 | 0.610.61 | 10.9910.99 | 9.249.24 | -- | 0.690.69 | 3.323.32 | |
| 14. | Biogen Pharmachem Industries LtdBIOGEN | BiotechnologyBiotechnology | 30.5430.54 | 0.290.29 | 35.5135.51 | 0.000.00 | -9.38-9.38 | -49.50-49.50 | -63.22-63.22 | 0.330.33 | -0.39-0.39 | 1.041.04 | -- | 0.000.00 | 3.643.64 | |
| 15. | Samsrita Labs LtdSAMSRITA | BiotechnologyBiotechnology | 24.2124.21 | 10.7910.79 | -2.97-2.97 | 1.411.41 | -9.35-9.35 | -41.04-41.04 | -57.74-57.74 | 2.062.06 | -68.80-68.80 | -73.27-73.27 | -- | 0.140.14 | 5.255.25 | |
| 16. | Transgene Biotek LtdTRABI | BiotechnologyBiotechnology | 22.8122.81 | 2.952.95 | -13.82-13.82 | -1.99-1.99 | -3.59-3.59 | 41.8341.83 | -38.67-38.67 | 2.272.27 | -6.46-6.46 | -0.45-0.45 | -- | 1.451.45 | 4.694.69 | |
| 17. | Groarc Industries India LtdGROARC | BiotechnologyBiotechnology | 11.7511.75 | 5.905.90 | 33.5733.57 | 2.792.79 | -3.59-3.59 | -10.74-10.74 | -22.67-22.67 | 0.290.29 | 0.870.87 | 1.121.12 | -- | 0.000.00 | 4.824.82 | |
| 18. | Genomic Valley Biotech LtdGVBL | BiotechnologyBiotechnology | 8.428.42 | 28.0028.00 | 210.38210.38 | 1.631.63 | -3.45-3.45 | 11.1111.11 | -42.26-42.26 | 2.162.16 | 9.159.15 | 1.281.28 | -- | 0.000.00 | 4.824.82 | |
| 19. | Hindustan Bio Sciences LtdHINDBIO | BiotechnologyBiotechnology | 7.387.38 | 7.127.12 | -92.26-92.26 | -1.11-1.11 | -2.82-2.82 | -1.79-1.79 | -16.24-16.24 | 8.208.20 | 11.7611.76 | -2.35-2.35 | -- | 2.792.79 | 3.903.90 |
Disclaimer: Please note that the above table is for informational purposes only, and is not recommendatory. Please do your own research or consult your financial advisor before investing. The data is derived from Tickertape Stock Screener and is subject to real-time updates.
Selection criteria: Sub-sector: Biotechnology | Market Cap: Sorted from Highest to Lowest
Selection criteria: Sub-sector: Biotechnology | Market Cap: Sorted from Highest to Lowest
Union Budget 2026-27 Updates Affecting the Biopharma Sector
In the Union Budget 2026–27, the Indian government unveiled several targeted measures to transform the biopharma and pharmaceutical ecosystem, with a clear focus on domestic manufacturing strength, research, regulatory efficiency, and access to critical therapies.
- Biopharma SHAKTI initiative: A flagship programme, Biopharma SHAKTI (Strategy for Healthcare Advancement Through Knowledge, Technology and Innovation), was announced with an outlay of ₹10,000 cr over the next 5 years. It aims to build a robust ecosystem for the domestic production of biologics and biosimilars and position India as a global biopharma manufacturing hub.
- Ecosystem development: Under the strategy, the Budget calls for a biopharma-focused network, including the creation of 3 new National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgrading of 7 existing ones to strengthen talent and research capacity.
- Clinical trial infrastructure: A network of over 1,000 accredited clinical trial sites across India will be established to support drug development, testing and global competitiveness.
- Regulatory strengthening: The Central Drugs Standard Control Organisation (CDSCO) is set for structural enhancements, with plans to bolster scientific review capacity and accelerate approval timeframes to align with global norms.
- Customs duty relief: The Budget provides basic customs duty exemption on 17 drugs, including critical cancer and rare disease treatments, to help improve affordability and access.
Overview of the Top Biotechnology Stocks in India
Biocon Ltd
Biocon is a biopharmaceutical company focused on biosimilars, generics, complex APIs and novel biologics research. Its products are used across areas such as diabetes, oncology and immunology, with a presence in both Indian and global healthcare markets.
Anthem Biosciences Ltd
Anthem Biosciences is a CRDMO company offering research, development and manufacturing services. It works across small molecules, peptides, lipids, oligonucleotides, high-potency APIs and large molecules, supporting pharma and biotech companies through the drug development cycle.
Acutaas Chemicals Ltd
Acutaas Chemicals manufactures pharmaceutical intermediates, speciality chemicals, semiconductor chemicals and battery materials. Its advanced pharma intermediates business serves global customers through regulated facilities, while its speciality chemicals portfolio caters to industries such as personal care, agriculture and fine chemicals.
Sai Life Sciences Ltd
Sai Life Sciences is a contract research, development and manufacturing organisation, or CRDMO. It supports global pharmaceutical and biotech companies with drug discovery, development and manufacturing services, helping them move molecules from early research to commercial production.
Onesource Specialty Pharma Ltd
Onesource Speciality Pharma is a speciality pharma CDMO with capabilities in biologics, sterile injectables, drug-device combinations and soft gelatin capsules. It supports pharmaceutical companies with development and manufacturing across complex dosage forms and therapeutic platforms.
What are Biotech Stocks in India?
Biotechnology stocks in India are shares of listed companies that use biological processes, living organisms or derived products for healthcare, pharmaceuticals, agriculture, industrial chemicals and environmental applications. Most listed biotech companies in India operate in healthcare and pharma, including biopharmaceuticals, biosimilars, vaccines, diagnostics and biotech-based APIs.
Overview of India’s Biotech Market
- India's biotechnology industry crossed $80 bn in revenue and is targeting $150 bn by 2025 and $300 bn by 2030, making it one of the fastest-growing biotech markets globally.
- The country is also the world’s 3rd-largest vaccine producer by volume and supplies nearly 60% of global demand for vaccines such as DPT, BCG and measles.
- There are over 800 biotechnology companies in India and more than 700 biosimilars approved for the market, the highest number of biosimilar approvals globally. The biopharmaceutical segment accounts for around 62% of India's total biotech revenue.
- The government's BioE3 Policy 2024 also aims to boost biotechnology-led innovation across healthcare, agriculture, clean energy and industrial processes.
How to Invest in Biotech Stocks?
Here's how you can invest in biotech stocks in India using Tickertape -
- Create an account on Tickertape or log in if you already have one.
- Select “Biotechnology” from the sector
- Analyse biotech stocks using 200+ parameters, including PE ratio, return on equity, revenue growth, R&D expense, debt-to-equity, and 1Y, 3Y, and 5Y returns.
- Analyse Stock Data: Tickertape provides comprehensive data on each stock, including financials, performance metrics, future projections, red flags, and more. You can review this data to assess each company’s health and potential in-depth.
- Add to Watchlist: You may keep track of potential investments by adding them to your watchlist.
- Invest Through Your Broker: Once you’ve decided on a stock, you can place a buy order through your brokerage account linked to Tickertape.
You can stay updated with each of your favourite stocks’ alerts and announcements with Tickertape Alerts. Further, you can analyse your overall portfolio and potential red flags in it by connecting it to Tickertape. Check out detailed analysis of your portfolio now!
Government Policy Supporting India’s Biotech Sector
- BioE3 Policy: Approved in August 2024, the BioE3 Policy focuses on high-performance biomanufacturing across biotherapeutics, smart proteins, climate-resilient agriculture, carbon capture and marine chemicals. It also targets a ₹10 lakh cr bioeconomy by 2030.
- PLI Scheme for Pharmaceuticals: The ₹15,000 cr PLI scheme supports fermentation-based APIs, biopharmaceutical ingredients, enzyme-based products and specialised pharma inputs, benefiting companies involved in complex API and biologics-linked manufacturing.
- PM-ABHIM: The ₹64,180 cr PM-Ayushman Bharat Health Infrastructure Mission supports public health infrastructure, including BSL laboratories and research facilities, helping strengthen India’s long-term biotech and healthcare research ecosystem.
Conclusion
India’s growing bioeconomy, strong pharma base and policy support can create opportunities for listed biotech companies. However, the sector also carries risks related to clinical trials, regulatory approvals, R&D costs, pricing pressure and global competition. Investors generally assess company fundamentals, product pipeline, compliance record, financial strength and valuation before evaluating biotech stocks.
You can use the Tickertape Stock Screener to filter and compare all listed biotech stocks in India by PE ratio, return on equity, revenue growth, debt-to-equity, and 1Y, 3Y, and 5Y returns.
Advantages of Investing in Biotech Stocks in India
Fast-Growing Bioeconomy
India’s bioeconomy reached $195.3 bn in 2025, up from $165 bn in 2024, reflecting an annual growth rate of around 18%. This growth is supported by biopharma, bio-industrial products, bio-agriculture, bio-services and biotech-led innovation.
Strong Vaccine and Pharma Base
India is a major global vaccine supplier, providing around 60% of UNICEF vaccine supplies and meeting 40-70% of global demand for DPT and BCG vaccines. This gives Indian biotech and pharma companies a strong base in biologics, vaccines and complex healthcare manufacturing.
Government Policy Support
The BioE3 Policy supports high-performance biomanufacturing, including precision biotherapeutics, smart proteins, climate-resilient agriculture and sustainable bio-based products. India is also targeting a $300 bn bioeconomy by 2030, which can support biotech-led manufacturing and R&D ecosystems.
Growth in Biotech Startups and Innovation
India has over 11,800 biotech startups, showing a strong innovation pipeline across healthcare, agriculture, industrial biotechnology and sustainability-led applications. This expands the ecosystem for listed biotech, CRAMS, CDMO and biopharma companies.
Global Outsourcing Opportunity
India’s cost-competitive and quality-certified manufacturing base supports demand for CRAMS, CDMO, API manufacturing, biosimilars and drug development services. Global pharma companies increasingly use India for research, clinical development and manufacturing support, creating opportunities for specialised listed players.
Risks of Investing in Biotech Stocks
High Research and Development Risk
Biotech companies often spend heavily on research, clinical trials and product development. Not every drug, biosimilar, vaccine or biotech product reaches commercial approval, which can affect revenue visibility and profitability.
Regulatory Approval Delays
Biotech products require approvals from Indian and global regulators. Delays, rejections, quality observations or compliance issues from agencies such as CDSCO, USFDA or EMA can affect launches, exports and manufacturing operations.
Long Commercialisation Cycles
Biotech products usually take years to move from research to market. This long development cycle can increase costs and delay returns, especially for companies dependent on new product pipelines.
Pricing and Margin Pressure
Biotech and pharma companies may face pricing pressure from government controls, global buyers, tender-based contracts and competition from generics or biosimilars. This can impact margins despite revenue growth.
Dependence on Global Markets
Many Indian biotech and CRAMS companies serve global pharma clients. Their performance can be affected by currency movements, export regulations, client concentration, geopolitical risks and changes in global outsourcing demand.
Technology and Competition Risk
Biotech is a fast-evolving sector. Companies need to keep investing in advanced manufacturing, biologics, biosimilars, enzymes and platform technologies. Firms that fail to upgrade may lose market share to domestic or global competitors.
Receive real-time market alerts for timely decisions
Monitor your portfolio from the palm of your hands
Watchlist stocks and mutual funds to stay updated
Factors to Consider Before Investing in Biotech Stocks
Clinical Trials and Regulatory Approvals
A biotech company's success often hinges on the outcomes of clinical trials and subsequent regulatory approvals. Monitoring these milestones is helpful as they can significantly influence stock performance and the biotech stock history.
Research and Development (R&D) Pipeline
You can assess the company's R&D pipeline, focusing on the number and stage of products under development. A robust pipeline indicates potential for future growth and revenue.
Partnerships and Collaborations
Strategic alliances with larger pharmaceutical companies on the list of biotech stocks can provide access to additional resources, expertise, and markets, enhancing the biotech firm's development and commercialisation capabilities.
Financial Health
You can examine key financial indicators such as revenue growth, profitability, and debt levels for a biotech stock analysis. A strong financial foundation enables sustained investment in research and development.
Market Demand and Competition
Evaluate the demand for the company's target products and the competitive landscape. Understanding market dynamics helps in assessing the potential for product adoption and profitability.
Regulatory Environment and Government Support
You can stay informed about government policies, tax incentives, and regulatory frameworks that can impact the biotech sector including the largest biotech stocks. Supportive government initiatives can foster innovation and growth.
Popular Stock Collections
Popular Mutual Fund Collections
Frequently Asked Questions on Biotech Stocks
What are biotech stocks?
Biotech stocks in India are shares of listed companies that use biological processes to develop products in healthcare, pharmaceuticals, and industrial applicationsWhat are the best biotech stocks in India?
As of 23rd June 2026, some of the best biotech stocks in India based on market capitalisation include:- Biocon Ltd
- Anthem Biosciences Ltd
- Acutaas Chemicals Ltd
- Sai Life Sciences Ltd
- Onesource Specialty Pharma Ltd
Disclaimer: The above list of biotechnology companies in India is for educational purposes only and should not be considered investment advice.What are the advantages of investing in biotech stocks?
Biotech stocks are linked to long-term themes such as healthcare demand, vaccine manufacturing, biosimilars, drug discovery, CRAMS and CDMO services. In India, the sector is also supported by a growing bioeconomy, government policies such as BioE3, rising global pharma outsourcing and demand for cost-efficient biologics and speciality medicines.
Disclaimer: The above information is for educational purposes only and should not be considered investment advice.What are the risks of investing in biotech stocks?
Biotech stocks can be risky because companies often face high R&D costs, long product development cycles, clinical trial uncertainty and regulatory approval delays. Their performance may also be affected by pricing pressure, quality observations, global competition, patent risks, export dependence and changing healthcare regulations.What are biopharma stocks in India?
Biopharma stocks (biopharmaceutical stocks) are a subset of biotech stocks, shares of companies that develop, manufacture, and commercialise drugs derived from biological sources rather than chemical synthesis.How can you invest in biotech stocks on Tickertape?
You can invest in biotech stocks on Tickertape. You can use the Tickertape screener to analyse listed biotech companies in India for parameters such as PE ratio, ROE, revenue growth, debt-to-equity ratio and 1Y, 3Y and 5Y returns. Once you select the stock, you can place an order through your broker account linked to Tickertape.
Disclaimer: The above information is for educational purposes only and should not be considered investment advice.
